Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>10x Genomics, a pioneer in single-cell and spatial transcriptomics, recently released its financial results for Q4 and the full year 2024.</li><li>The company experienced a 1% decrease in total revenue year-over-year, ending with $611 million.</li><li>This was largely due to challenges stemming from macroeconomic conditions and significant changes within the company.</li></ul>

10x Genomics, a pioneer in single-cell and spatial transcriptomics, recently released its financial results for Q4 and the full year 2024.The company experienced a 1% decrease in total revenue year-over-year, ending with $611 million.This was largely due to challenges stemming from macroeconomic conditions and significant changes within the company.

10x Genomics: Expanding Footprint Within Biopharma Sector To Shape Their Future!

Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

<ul>
<li>Aptamer Group 0.33p £6.57m (APTA.L) The developer of novel Optimer binders to enable innovation in the life sciences industry yesterday reported Interims to December 2024.</li>
<li>Its revenue improved to £0.7m from £0.3m with an EBITDA loss of £1.1m down from £1.8m, while net cash is £2m after raising funds last year at 0.2p.</li>
<li>The strategy is to create value through the development of high-value Optimer assets with licensing potential through commercial partners, while generating revenues from fee-for-service work, which has a 43% gross margin. </li>
</ul>


Aptamer Group 0.33p £6.57m (APTA.L) The developer of novel Optimer binders to enable innovation in the life sciences industry yesterday reported Interims to December 2024.
Its revenue improved to £0.7m from £0.3m with an EBITDA loss of £1.1m down from £1.8m, while net cash is £2m after raising funds last year at 0.2p.
The strategy is to create value through the development of high-value Optimer assets with licensing potential through commercial partners, while generating revenues from fee-for-service work, which has a 43% gross margin. 


10X Genomics Inc-Class A - Hybridan Small Cap Feast: 12/03/2025

<ul><li>10x Genomics, a leading biotechnology company, presented its financial results for the third quarter ended September 30, 2024, during which the company experienced a 1% year-over-year decline in revenue.</li><li>This outcome was primarily attributed to disruptions stemming from a sales restructuring initiative and cautious customer spending amid a challenging macroeconomic environment.</li><li>As a consequence, the company has revised its full-year revenue projection to between $595 million and $605 million, indicating a 3% decrease from the previous year.</li></ul>

10x Genomics, a leading biotechnology company, presented its financial results for the third quarter ended September 30, 2024, during which the company experienced a 1% year-over-year decline in revenue.This outcome was primarily attributed to disruptions stemming from a sales restructuring initiative and cautious customer spending amid a challenging macroeconomic environment.As a consequence, the company has revised its full-year revenue projection to between $595 million and $605 million, indicating a 3% decrease from the previous year.

10x Genomics Inc.: What Are Their Recent Single-Cell & Spatial Technology Advancements? - Major Drivers

<ul><li>10x Genomics, a leader in single-cell and spatial technologies, presented a mixed financial and operational report for Q2 2024, characterized by modest revenue growth alongside strategic advancements and evident pressures from the external economic environment.</li><li>On the financial front, 10x Genomics reported a revenue increment of 4% year-over-year, reaching $153 million, driven particularly by robust demand for spatial consumables and a sequential increase in single-cell consumables.</li><li>Notably, the company achieved a free cash flow positive status during the quarter.</li></ul>

10x Genomics, a leader in single-cell and spatial technologies, presented a mixed financial and operational report for Q2 2024, characterized by modest revenue growth alongside strategic advancements and evident pressures from the external economic environment.On the financial front, 10x Genomics reported a revenue increment of 4% year-over-year, reaching $153 million, driven particularly by robust demand for spatial consumables and a sequential increase in single-cell consumables.Notably, the company achieved a free cash flow positive status during the quarter.

10x Genomics Inc.: How Are They Adapting to Market Conditions & Customer Needs? - Major Drivers

<ul><li>10x Genomics recently disclosed its financial results for the first quarter ended March 31, 2024, showcasing a revenue increase of 5% to $141 million.</li><li>The company's earnings overview indicates a mixed performance with significant developments in its product offerings that could influence its future market positioning, financial health, and competitive edge.</li><li>Positively, 10x Genomics reported robust growth in its spatial biology segment, primarily fueled by its Visium franchise and the launch of Visium HD.</li></ul>

10x Genomics recently disclosed its financial results for the first quarter ended March 31, 2024, showcasing a revenue increase of 5% to $141 million.The company's earnings overview indicates a mixed performance with significant developments in its product offerings that could influence its future market positioning, financial health, and competitive edge.Positively, 10x Genomics reported robust growth in its spatial biology segment, primarily fueled by its Visium franchise and the launch of Visium HD.

10x Genomics Inc.: Expansion into the Spatial Genomics Market & Other Major Drivers

United States

10X Genomics, Inc. operates as a life science and diagnostics company. The Company develops software for analyzing biological systems such as genetic and immune cells. 10X Genomics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

10X Genomics (TXG US)

10x Genomics: Expanding Footprint Within Biopharma Sector To Shape Their Future!

10x Genomics, a pioneer in single-cell and spatial transcriptomics, recently released its financial results for Q4 and the full year 2024. The...

Baptista Research

10X Genomics Inc-Class A - Hybridan Small Cap Feast: 12/03/2025

Aptamer Group 0.33p £6.57m (APTA.L) The developer of novel Optimer binders to enable innovation in the life sciences industry yesterday reported...

Hybridan

10x Genomics Inc.: What Are Their Recent Single-Cell & Spatial Technology Advancements? - Major Drivers

10x Genomics, a leading biotechnology company, presented its financial results for the third quarter ended September 30, 2024, during which the...

Baptista Research

10x Genomics Inc.: How Are They Adapting to Market Conditions & Customer Needs? - Major Drivers

10x Genomics, a leader in single-cell and spatial technologies, presented a mixed financial and operational report for Q2 2024, characterized by...

Baptista Research

10x Genomics Inc.: Expansion into the Spatial Genomics Market & Other Major Drivers

10x Genomics recently disclosed its financial results for the first quarter ended March 31, 2024, showcasing a revenue increase of 5% to $141...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)